Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data45
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs30
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data28
Economic evaluation in psychiatric pharmacogenomics: a systematic review28
Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium23
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy21
Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy18
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study16
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle16
Does the RAAS play a role in loss of taste and smell during COVID-19 infections?15
Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan14
Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis14
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection14
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States13
Pharmacogenetic information in Swiss drug labels – a systematic analysis13
Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications13
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population12
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience12
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders11
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel11
The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA10
Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis9
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review9
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review9
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-199
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model9
Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis9
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review8
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis8
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore8
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment8
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis7
Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists7
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice7
Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population7
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals7
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges7
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer7
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?6
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors6
Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China6
Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes6
Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers6
A review of the existing literature on buprenorphine pharmacogenomics6
The need of a multicomponent guiding approach to personalize clopidogrel treatment6
0.020947933197021